Evidence map›Paper›PMID 42005403›Full record

ArticleInternational journal of cardiology. Heart & vasculature2026

Time trends in ICD recommendations and predictors of device activation hypertrophic cardiomyopathy: a real-world cohort study.

Miguel Marques Antunes, Ricardo Carvalheiro, Isabel Cardoso, Hélder Santos, Vaz Vera Ferreira, Inês Grácio de Almeida, Pedro Silva Cunha, Daniel Caldeira, António Fiarresga, Nuno Cardim and 3 more

Abstract read
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Miguel Marques AntunesHospital de Santa Marta, Serviço de Cardiologia, Centro Clinico Académico de Lisboa (CCAL), Lisboa, Portugal.
Ricardo CarvalheiroHospital de Santa Marta, Serviço de Cardiologia, Centro Clinico Académico de Lisboa (CCAL), Lisboa, Portugal.
Isabel CardosoHospital de Santa Marta, Serviço de Cardiologia, Centro Clinico Académico de Lisboa (CCAL), Lisboa, Portugal.
Hélder SantosHospital de Santa Marta, Serviço de Cardiologia, Centro Clinico Académico de Lisboa (CCAL), Lisboa, Portugal.
Vaz Vera FerreiraHospital de Santa Marta, Serviço de Cardiologia, Centro Clinico Académico de Lisboa (CCAL), Lisboa, Portugal.
Inês Grácio de AlmeidaHospital de Santa Marta, Serviço de Cardiologia, Centro Clinico Académico de Lisboa (CCAL), Lisboa, Portugal.
Pedro Silva CunhaHospital de Santa Marta, Serviço de Cardiologia, Centro Clinico Académico de Lisboa (CCAL), Lisboa, Portugal.
Daniel CaldeiraCentro Cardiovascular da Universidade de Lisboa - CCUL@RISE, Lisboa, Portugal.
António FiarresgaHospital de Santa Marta, Serviço de Cardiologia, Centro Clinico Académico de Lisboa (CCAL), Lisboa, Portugal.
Nuno CardimNOVA Medical School, Faculdade de Ciências Médicas, Portugal.
Rui Cruz FerreiraHospital de Santa Marta, Serviço de Cardiologia, Centro Clinico Académico de Lisboa (CCAL), Lisboa, Portugal.
Mário Martins OliveiraHospital de Santa Marta, Serviço de Cardiologia, Centro Clinico Académico de Lisboa (CCAL), Lisboa, Portugal.
Sílvia Aguiar RosaHospital de Santa Marta, Serviço de Cardiologia, Centro Clinico Académico de Lisboa (CCAL), Lisboa, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Sudden cardiac death (SCD) remains a major concern in hypertrophic cardiomyopathy (HCM). Over recent years, European Society of Cardiology (ESC) guidelines have broadened recommendations for implantable cardioverter defibrillator (ICD) implantation in primary prevention. We aimed to evaluate clinical outcomes and event detection in an HCM primary prevention cohort, while assessing how these evolving criteria translate into real-world ICD eligibility and event detection. Methods: We conducted a single-centre retrospective study including 52 consecutive HCM patients who received an ICD for primary prevention between 2014 and 2024. Baseline clinical, imaging, and follow-up data were collected. The primary endpoint was appropriate ICD therapy for ventricular tachycardia or fibrillation. Patients were classified according to the 2014, 2022, and 2023 ESC guidelines. Time-to-event analyses using univariate Cox regression were performed to identify predictors of ICD activation. Results: Over a median follow-up of 2.2 years, 6 patients (12%) experienced appropriate ICD therapy. According to ESC classifications, the 2022/2023 guidelines would have increased ICD eligibility by about 50% compared with the 2014 guideline, mainly due to the inclusion of extensive late gadolinium enhancement on CMR and reduced LVEF (<50%) as risk enhancers. However, no guideline set identified all patients who developed ventricular arrhythmias, and a subset of patients with events would not have been eligible for ICD implantation under any ESC recommendation. Lower LVEF was associated with higher risk of ICD activation. Conclusions: Successive ESC guidelines have lowered the threshold for ICD implantation in HCM, increasing eligibility but also implantations in event-free patients. Persistent event occurrence in ineligible individuals highlights the need for refined prediction models and individualized clinical judgment, including complementary tools such as ILR monitoring.

Indexed as

Hypertrophic cardiomyopathyImplantable cardiac defibrillatorSudden cardiac deathVentricular tachycardiaVentricullar fibrillation

Identifiers

PMID42005403
PMCPMC13090688

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.